Linerixibat (GSK2330672) granted Orphan Status
Linerixibat (GSK2330672), a drug that is being developed for PBC patients who experience itchiness, has recently been granted “orphan” status by the FDA. This is wonderful news for patients who
Phase 3 now enrolling
As a result of extremely promising results of Phase 2 trials, Cymabay Therapeutics is now enrolling patients in a Phase 3 study for Seladelpar. This is a 52 week triple
Results of our Patient Survey
Read the results of our patient survey which was initiated in 2015, with more than 250 PBC patients reporting how PBC affects their daily lives. We worked with a research
Promising Interim Results for Phase 2 Trial
Genkyotex “published interim efficacy results today, GKT831 met both it’s primary and secondary endpoints in the Phase II PBC trial! A big thank you to the patients who participate in theHow do you Diagnose PBC?
The Toronto Centre for Liver Disease recently published a graphic that explains how specialists diagnose PBC. Thanks to Dr. Gideon Hirschfield and Marwa Ismail for this concise explanation.
Download the graphic here.
Your Liver & Cirrhosis
Thanks to the Gastrointestinal Society in association with the Canadian Society of Intestinal Research for this excellent graphic describing Liver Cirrhosis and providing you with a tool to discuss your
Phase 2 trial for PBC non-bile acid FXR agonist cancelled
Novartis has cancelled its phase II trial for a non-bile acid FXR agonist in patients with PBC.
Anti-depressant may help PBC
A new study from the University of Calgary shows the antidepressant, Mitrazapine, may help PBC. In April Dr Abdel Aziz presented the promising results. Read more here.
Proof of Concept clinical trial – Australia & New Zealand
More exciting news for PBC patients and their families. Arena Pharmaceutical is beginning a proof of concept clinical trial in Australia and New Zealand for Etrasimod. Read more.